Trevena Reports First Quarter 2016 Financial Results and Provides Corporate Update May 05, 2016 7:00am EDT
Trevena Announces Successful End-of-Phase 2 Meeting with FDA and Outlines Phase 3 Program for Oliceridine May 02, 2016 4:01pm EDT
Trevena Announces BLAST-AHF Phase 2b Trial Results will be Presented at the Heart Failure 2016 Conference Apr 15, 2016 7:00am EDT
Trevena to Present at the Needham & Company 15th Annual Healthcare Conference Apr 07, 2016 7:00am EDT
Trevena Announces Presentations at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting Mar 31, 2016 7:00am EDT
Trevena to Host Conference Call on March 9th to Discuss Full Year 2015 Financial Results Mar 02, 2016 4:01pm EST
Trevena, Inc. Receives FDA Breakthrough Therapy Designation for Oliceridine for the Management of Moderate-to-Severe Acute Pain Feb 22, 2016 7:00am EST
Trevena to present at the 2016 RBC Capital Markets' Global Healthcare Conference Feb 17, 2016 7:00am EST
